BVS earnings analysis
What we found in BVS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Bioventus reported Q1 2026 revenue of $132.1 million and EPS of $0.04, exceeding estimates. Both U.S. and International segments showed growth, with total net sales increasing 6.6% year-over-year. Management highlighted strong cash flow and reduced debt, keying on an optimistic outlook for the year.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Beat Estimates
- Q1 2026 revenue of $132.1 million exceeded estimates by $2.4 million, a 6.6% increase from $123.9 million in Q1 2025.
- Improved EPS
- Earnings per share reported at $0.04, recovering from a loss of $0.04 in the prior year.
- Strong Cash Flow
- Net cash from operating activities increased by $28.3 million year-over-year, totaling $8.9 million.
- Debt Reduction
- Discretionary prepayments of $22.0 million on long-term debt were made, helping to reduce interest expenses.
- Segment Growth
- International net sales grew by 17.1% year-over-year, totaling $15.6 million, driven by Pain Treatments and Surgical Solutions.
- Increased Adjusted EBITDA
- Adjusted EBITDA grew to $23.9 million, up from $19.2 million, marking a 24% increase year-over-year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Regulatory Investigations
- Shareholder litigation continues against the company, raising potential legal risks.
- High Dependence on Receivables
- Management hinted at potential issues if cash flow trends reverse due to elevated receivables.
- Interest Rate Vulnerability
- Rising interest rates could impact future financing costs, affecting profitability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.04
- Gross margin
- 68.7%
- Operating margin
- 6.4%
- Segment
- U.S. Pain Treatments: $56.2M
- Segment
- U.S. Surgical Solutions: $42.5M
- Segment
- U.S. Restorative Therapies: $17.7M
- Segment
- International Pain Treatments: $7.3M
- Segment
- International Surgical Solutions: $5.5M
- Segment
- International Restorative Therapies: $2.9M
What they said about what is next.
Raised guidance for Non-GAAP EPS and cash from operations.
The filing reads better than the one before it.
What came before.
- 10-K · March 5, 2026
- Bioventus closed FY2025 with stable top-line (FY2025 revenue ~$569.0M) while delivering meaningfully higher profitability and cash generation versus FY2024. Management highlights regulatory progress in PNS (510(k)…
- 10-K · March 11, 2025
- Bioventus positions itself as a specialist musculoskeletal medical device company organized across Pain Treatments, Surgical Solutions and Restorative Therapies, and emphasizes expansion of its neXus/BoneScalpel…
- 10-Q · August 6, 2024
- Bioventus reported Q2 net sales of $151,217 (vs $137,069 a year ago), with gross profit of $103,639 (≈68.6% margin). Despite top-line growth and positive operating cash flow year-to-date, the quarter included a $31,870…
- 10-Q · November 21, 2022
- Bioventus reported Q3 net sales of $128,662,000, up from $108,890,000 a year ago (+$19.8M, +18.2%), but posted a large operating loss of $(200,855,000) driven principally by a $189,197,000 goodwill impairment. Gross…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BVS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever